Meng X, Pang H, Sun F, Jin X, Wang B, Yao K, Yao L, Wang L, Hu Z
Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11) Diabetes Care
Among initiators of GLP1 receptor agonists versus SGLT2 inhibitors, the direction of effect modification by age in two prior studies [16, 25] was conflicting, and the direction of effect modification by cardiovascular disease and sex in our study disputes prior evidence [16, 25]
Immunogenicity of therapeutic peptide products: bridging the gaps regarding the role of product-related risk factors
Ghrelin in the EGCG group also decreased after the 16-week course but did not achieve statistical significance
Wheres the streetlight shining